Evgen Pharma PLC Result of AGM (2586C)
25 June 2016 - 12:36AM
UK Regulatory
TIDMEVG
RNS Number : 2586C
Evgen Pharma PLC
24 June 2016
For immediate release 24 June 2016
Evgen Pharma plc
Result of AGM
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, confirms that all resolutions were duly passed at its
Annual General Meeting held today.
Enquiries:
Evgen Pharma plc c/o +44 (0)
Dr Stephen Franklin, CEO 20 7466 5000
www.evgen.com
Buchanan
Mark Court, Sophie Cowles, Stephanie +44 (0) 20
Watson 7466 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney, Margarita
Mitropoulou (Corporate Finance) +44 (0) 20
John Howes (Corporate Broking) 7382 1100
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. It is also carrying out preclinical work in
multiple sclerosis and has a clinical interest in prostate cancer.
The Company's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and is based
in Liverpool, UK, at the Liverpool Science Park. It joined the AIM
market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG. For further information please visit
www.evgen.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGEALKLADLKEFF
(END) Dow Jones Newswires
June 24, 2016 10:36 ET (14:36 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024